ZIOPHARM ONCOLOGY INC's ticker is ZIOP and the CUSIP is 98973P101. A total of 128 filers reported holding ZIOPHARM ONCOLOGY INC in Q2 2017. The put-call ratio across all filers is 1.69 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $5,932 | -17.4% | 11,557 | 0.0% | 0.00% | – |
| Q1 2023 | $7,180 | -4.3% | 11,557 | 0.0% | 0.00% | – |
| Q4 2022 | $7,501 | -62.5% | 11,557 | 0.0% | 0.00% | -100.0% |
| Q3 2022 | $20,000 | 0.0% | 11,557 | -62.0% | 0.00% | 0.0% |
| Q1 2022 | $20,000 | -39.4% | 30,402 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $33,000 | -46.8% | 30,402 | -0.5% | 0.00% | -50.0% |
| Q3 2021 | $62,000 | -29.5% | 30,568 | 0.0% | 0.00% | -33.3% |
| Q2 2021 | $88,000 | +6.0% | 30,568 | +33.8% | 0.00% | 0.0% |
| Q1 2021 | $83,000 | -42.4% | 22,852 | -1.1% | 0.00% | -87.5% |
| Q3 2017 | $144,000 | +77.8% | 23,099 | +78.8% | 0.02% | +60.0% |
| Q2 2017 | $81,000 | +2.5% | 12,922 | -7.5% | 0.02% | 0.0% |
| Q3 2016 | $79,000 | +426.7% | 13,966 | +365.5% | 0.02% | – |
| Q4 2014 | $15,000 | -99.9% | 3,000 | 0.0% | 0.00% | -100.0% |
| Q2 2014 | $12,090,000 | – | 3,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 9,709,607 | $60,394,000 | 3.07% |
| MSD Partners, L.P. | 3,410,500 | $21,213,000 | 1.32% |
| MILLER VALUE PARTNERS, LLC | 4,926,456 | $30,643,000 | 1.24% |
| Michael & Susan Dell Foundation | 66,749 | $415,000 | 0.33% |
| ACUTA CAPITAL PARTNERS, LLC | 150,000 | $933,000 | 0.26% |
| Piermont Capital Management Inc. | 85,500 | $532,000 | 0.15% |
| A.R.T. Advisors, LLC | 411,547 | $2,559,000 | 0.14% |
| EQUITEC PROPRIETARY MARKETS, LLC | 96,100 | $598,000 | 0.14% |
| Vident Investment Advisory, LLC | 204,744 | $1,274,000 | 0.10% |
| EQUITEC PROPRIETARY MARKETS, LLC | 68,800 | $428,000 | 0.10% |